Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > The 23 Optimized Patients

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Apr 05, 2022 2:55pm

188 Views

Post# 34577795

RE:RE:The 23 Optimized Patients

Hi MineDigger. I don't understand that part of the news release either.

MineDigger wrote:
Eog, thanks for that "dissection" of the data, so any chance you also "dissect" this highlighted part of this sentence for me

"The Study II optimized treatment patients, who received either an optimized primary study treatment or optimized maintenance study treatment consisted of: 23 patients at 90 days, 26 patients at 180 days and 27 patients at each of 270, 360 and 450 days."

To me it reads as if it is saying we really have 27 patients who have gone all the way to 450 days (surely not true but I don't spend as long on TLT as I used to), but even without knowing what the true 450 day figure is, what I can't fathom is in what sense there can be a higher number for 450 days (27) than there is for 90 days (23), can you or anyone explain?

And just for the benefit of having more data in one place I have taken the liberty of merging in some of your other figures in your final sentence to give me:

As the news release makes explicit there is still the potential of 82.6 CR (19) at 90 days for the 23 optimized patients (52.2% CR (12) + 17.4% PR (4) + 13% pending (3)), and meaning there is a 17% No Response (4).

Cheers

MD